Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(3S)-N,N'-bis-(t-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid is a pyridazine derivative commonly used in the pharmaceutical industry. It is an important intermediate in the synthesis of various pharmaceutical drugs due to its biological activity. The t-butoxycarbonyl groups in the compound act as protective groups that can be removed under mild conditions to reveal the active functional groups, making it a crucial chemical in the field of medicinal chemistry.

156699-39-7

Post Buying Request

156699-39-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (3S)-1,2-bis[(2-methylpropan-2-yl)oxycarbonyl]diazinane-3-carboxylic acid

    Cas No: 156699-39-7

  • USD $ 1.9-2.9 / Gram

  • 100 Gram

  • 1000 Metric Ton/Month

  • Chemlyte Solutions
  • Contact Supplier

156699-39-7 Usage

Uses

Used in Pharmaceutical Industry:
(3S)-N,N'-bis-(t-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid is used as an intermediate in the synthesis of various pharmaceutical drugs for its biological activity and the ability to uncover active functional groups by removing the protective t-butoxycarbonyl groups under mild conditions.
Used in Medicinal Chemistry:
(3S)-N,N'-bis-(t-butoxycarbonyl)hexahydropyridazine-3-carboxylic acid is used as a key chemical in the development of new drugs and medications, contributing to the advancement of medicinal chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 156699-39-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,6,9 and 9 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 156699-39:
(8*1)+(7*5)+(6*6)+(5*6)+(4*9)+(3*9)+(2*3)+(1*9)=187
187 % 10 = 7
So 156699-39-7 is a valid CAS Registry Number.

156699-39-7Downstream Products

156699-39-7Relevant articles and documents

Total synthesis and structure elucidation of JBIR-39: A linear hexapeptide possessing piperazic acid and γ-hydroxypiperazic acid residues

Yoshida, Masahito,Sekioka, Naoki,Izumikawa, Miho,Kozone, Ikuko,Takagi, Motoki,Shin-ya, Kazuo,Doi, Takayuki

supporting information, p. 3031 - 3041 (2015/02/05)

The total synthesis and stereochemical structural elucidation of JBIR-39, containing four nonproteinogenic piperazic acid (Piz) residues, is reported. The synthesis includes Sc(OTf)3-catalyzed acylation of a Piz(γ-OTBS) derivative with piperazi

Synthesis of the southern tripeptide (C1-N12) of sanglifehrins using asymmetric organocatalysis

Radhika, Laghuvarapu,Chandrasekhar, Srivari

supporting information, p. 3602 - 3609 (2015/08/11)

The tripeptide southern region of the novel cyclophilin binding natural product macrolides, namely sanglifehrins, is synthesized involving asymmetric organocatalysis as chirality-inducing step. List's asymmetric α-amination was used in the synthesis of th

Synthesis of the tripeptide domain of sanglifehrins using asymmetric phase-transfer catalysis

White, James D.,Suttisintong, Khomson

, p. 2757 - 2762 (2013/04/23)

The tripeptide (S)-valinyl-(S)-m-hydroxyphenylalanyl-(3S)-piperazate common to immunosuppressant sanglifehrins was synthesized from the constituent amino acid residues in nine steps and 42% overall yield. A key construction was the installation of (S) absolute configuration in m-hydroxyphenylalanine using asymmetric phase-transfer catalysis in the presence of N-(1-naphthyl) cinchonidinium bromide. Cbz-protected (S)-valine was first coupled to the amino group of (S)-m-triisopropylsilyloxyphenylalanine tert-butyl ester, and the resulting dipeptide after ester cleavage was linked to (3S)-methyl piperazate.

Total synthesis of NW-G01, a cyclic hexapeptide antibiotic, and 34-epi-NW-G01

Shibahara, Setsuya,Matsubara, Takaaki,Takahashi, Keisuke,Ishihara, Jun,Hatakeyama, Susumi

, p. 4700 - 4703 (2011/11/06)

NW-G01, a cyclic hexapeptide antibiotic, and 34-epi-NW-G01 were synthesized by the highly stereoselective convergent approach for the first time, thereby unambiguously determining the absolute structure of NW-G01.

Stereochemical Definition and Chirospecific Synthesis of the Peptide Deformylase Inhibitor Sch 382583

Coats, Reed A.,Lee, Sheng-Lian,Davis, Kari A.,Patel, Kanu M.,Rhoads, Elaine K.,Howard, Michael H.

, p. 1734 - 1737 (2007/10/03)

The recently reported natural product Sch 382583 (1), an inhibitor of peptide deformylase, has been synthesized in 16 steps from commercially available starting materials. The three chiral centers were set by a combination of chiral auxiliary and chiral p

A convergent three-component total synthesis of the powerful immunosuppressant (-)-sanglifehrin A

Paquette, Leo A.,Duan, Maosheng,Konetzki, Ingo,Kempmann, Christoph

, p. 4257 - 4270 (2007/10/03)

The potent immunosuppressive agent (-)-sanglifehrin A (5), initially discovered in a soil sample from Malawi, has been synthesized in a highly conver soil gent and stereocontrolled manner. The enantioselective approach relies on initial construction of th

An efficient stereoselective synthesis of [3S(1S,9S)]-3-[[[9- (benzoylamino)octahydro-6,10-dioxo-6H-pyridazino-(1,2-a)(1,2)-diazepin-1- yl]-carbonyl]amino]-4-oxobutanoic acid, an interleukin converting enzyme (ICE) inhibitor

Chen,Goel,Hyun,Magano,Rubin

, p. 1587 - 1592 (2007/10/03)

The title compound 1 is a potent interleukin-1β-converting enzyme (ICE) inhibitor. Recently, an efficient chiral synthesis of compound 1 has been accomplished in our labs. The overall yield of this 18-step stereoselective synthesis was 9.8%.

Enantioselective synthesis of (3R)- and (3S)-piperazic acids. The comparative unimportance of DMPU mediated retro-hydrazination

Hale, Karl J.,Cai, Jiaqiang,Delisser, Vern,Manaviazar, Soraya,Peak, S. Andrew,Bhatia, Gurpreet S.,Collins, Timothy C.,Jogiya, Neha

, p. 1047 - 1068 (2007/10/03)

In response to a recent literature report by Decicco and Leathers, the work of Hale, Delisser, and Manaviazar (1992) on the asymmetric synthesis of (3R)- and (3S)-piperazic acids has been reinvestigated, and the originally claimed product yields fully substantiated. The claims made in reference 13 about the proportions of cyclised product 6 and starting bromide 20 isolated from the low temperature electrophilic hydrazination-nucleophilic cyclisation of 20 with di-t-butylazodicarboxylate (DBAD) and DMPU as an additive are inaccurate. The retro-hydrazination reaction that they claim is problematic when DMPU is added to the hydrazinated reaction mixture has been demonstrated not to have a seriously detrimental effect on cyclisation product yield and to be unimportant. The other main ion of reference 13, that the electrophilic hydrazination and nucleophilic cyclisation of 20 gives 6 in 91% isolated yield when n-Bu4NI is employed as an additive (instead of DMPU) has also been shown to be in error. We have carefully repeated a scaled-down version of the n-Bu4NI catalysed procedure and have found that 6 is generally isolated in yields of 50-56% after flash chromatography. We have concluded that n-Bu4NI does not significantly increase the yields of cyclisation products 6 or 17 when it is employed as a cyclisation additive. Herein, we report details of our two preferred 'crude' experimental procedures for preparing the enantiomers of piperazic acid in high optical purity, neither of which requires chromatographic purification of the reaction intermediates en route. Both these preferred 'crude' methods for preparing 11 and 19 have been consistently reproduced many times in these laboratories over the past few years. In our view, they remain the most expedient and highest yielding methods currently available for obtaining 11 and 19 in high optical purity.

AZINOTHRICIN SYNTHETIC STUDIES. 1. EFFICIENT ASYMMETRIC SNTHESES OF (3R)- AND (3S)-PIPERAZIC ACIDS

Hale, Karl J.,Delisser, Vern M.,Manaviazar, Soraya

, p. 7613 - 7616 (2007/10/02)

A convenient asymmetric synthesis of both (3R)-and (3S)-piperazic acids has been developed that is based on electrophilic hydrazination of a chiral bromovaleryl carboximide enolate with di-tert-butyl azodicarboxylate, followed by subsequent intramolecular

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 156699-39-7